Top cloud trends for the pharmaceutical industry

Posted:

Several significant trends have shaped the pharmaceutical ecosystem over the last few years. More recently we have witnessed an increasing need to develop personalised medicines which is adding to the complexity of care. A flurry of mergers and acquisitions have created huge, competing conglomerates, while stringent regulation and tighter price controls have forced many firms to find cost-saving measures, all the while paying close attention to evolving compliance needs. It’s no surprise then that many pharmaceutical companies have found it necessary to change their business models and leverage new technologies such as public cloud in order to cope with demands.

But how exactly can public cloud benefit the sector?

Process and access data faster

Nowhere is public cloud more effective than within the research and development community. This process is a long and arduous one with incredible amounts of time, labour and resources needed to complete the process. With only 1 in every 5,000 drugs ever making its way into the market, it’s clear the investment risk is huge.  For the drugs that successfully make it to the marketplace, it often takes at least 10 years to develop them to the standard of quality and safety necessary, meaning costs can total up to £1.15 billion before the drug is even licensed for use.  With such hefty time frames and budgets, cloud technology could be the ideal resolution. It can help pharmaceutical companies process the huge amounts of data they deal with as part of research and development, and replace the information silos that have been formed as a result of legacy infrastructure.

Streamline collaboration

The globalisation of healthcare has made it essential to be able to work with a range of partners, including biotech firms, research laboratories and academic institutions located around the world.  Pharmaceutical organisations may have offices, sites and facilities scattered across the country and overseas, making the communication process cumbersome. However, with the adoption of public cloud technology, there is scope to integrate and standardise these information flows to create a truly efficient, streamlined collaboration platform.

The cloud also grants pharmaceutical companies greater control over their scalability potential. SaaS computing enables a ‘plug-in and play’ solution, where companies can use the services they require at any location and on any device. As a result, teams can quickly be scaled up or down depending on the project, and be comprised of individual workers located anywhere in the world. But most importantly, it allows companies to quickly and efficiently deliver the value of clinical research.  Data, including lab, imagery and statistical analysis data, can all be delivered at speed thanks to cloud-based infrastructure. These productivity savings, coupled with the operational savings gained from obsolete hardware maintenance, can all be put back into research and development efforts.

Address the Security Fears

While the industry may still be in the early days of cloud adoption, for many the key barrier to adoption is security. Pharmaceutical companies hold vast amounts of sensitive data, including intellectual property and patient information. As a result, the need to protect this information is paramount to business survival.

Myths around the security of cloud computing which paint a picture that cloud is inherently less secure than traditional approaches, often stems from the fact that the approach itself feels insecure, with data stored on servers and systems you don’t own or control. However, control does not mean security and today, cloud is considered to be more secure than traditional systems, generally speaking.

Crucially, whether cloud or on-premise, the system is only as secure as the amount of planning, expertise and technology that goes into the data and applications, which is why it is vital that the sector partners with an appropriate cloud provider that has additional security measures in place.

Partner with a Cloud Provider that puts Security First

To provide this extra layer of security and reassurance, ANS has partnered with security-as-a-service cloud solution provider, Alert Logic. Alert Logic has more than a decade of experience delivering deep security insight and continuous protection for customers by providing cloud security solutions that are flexible and designed to work with hosting and cloud service providers such as ANS.

The partnership is enabling ANS to offer complete security services across all platforms supported by the business, helping the pharmaceutical industry exercise stringent security measures across hyper-scale cloud platforms and ensuring end-to-end security for critical applications.   

So what’s next?

Pharmaceutical companies must ensure their technological infrastructure is prepared for the demands of tomorrow. The industry needs an innovative way to manage the new business paradigm with greater agility, reduced costs and increased security and compliance.

To find out more about ANS’ partnership with Alert Logic, click here. Alternatively, to learn how ANS’ public cloud solutions can help your pharmaceutical organisation to increase efficiency and reduce costs, click here.